carmustine has been researched along with Carcinoma, Hepatocellular in 15 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In both HepG2 and J5 HCC cell lines, a synergistic antiproliferative effect was observed when a low dosage of BP was combined with the chemotherapeutic drug 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)." | 5.36 | Extended O6-methylguanine methyltransferase promoter hypermethylation following n-butylidenephthalide combined with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) on inhibition of human hepatocellular carcinoma cell growth. ( Chan, DC; Chen, YL; Harn, HJ; Jian, MH; Lin, CC; Lin, PC; Lin, SZ; Su, CC; Su, KJ; Tseng, IH; Wei, CW; Yu, SL; Yu, YL, 2010) |
| " In both HepG2 and J5 HCC cell lines, a synergistic antiproliferative effect was observed when a low dosage of BP was combined with the chemotherapeutic drug 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)." | 1.36 | Extended O6-methylguanine methyltransferase promoter hypermethylation following n-butylidenephthalide combined with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) on inhibition of human hepatocellular carcinoma cell growth. ( Chan, DC; Chen, YL; Harn, HJ; Jian, MH; Lin, CC; Lin, PC; Lin, SZ; Su, CC; Su, KJ; Tseng, IH; Wei, CW; Yu, SL; Yu, YL, 2010) |
| "Treatment of rat hepatoma cells (H4 cells) with various DNA-damaging agents increases the number of O6-methylguanine-DNA-methyltransferase (transferase) molecules per cell." | 1.28 | Enhancement of 1,3-bis(2-chloroethyl)-1-nitrosourea resistance by gamma-irradiation or drug pretreatment in rat hepatoma cells. ( Habraken, Y; Laval, F, 1991) |
| "In nine of 11 (82%) instances, tumors were sensitive to a particular drug, and the patient had at least 50% regression of tumor following treatment with the tested drug." | 1.26 | Clinical correlations with drug sensitivities in the clonogenic assay: a retrospective study. ( Burk, MW; Campbell, MA; Giuliano, AE; Kaiser, LR; Kern, DH; Mann, BD; Morton, DL, 1982) |
| "A case of hepatocellular carcinoma in a young female is presented in which the apparent etiology was the use of oral contraceptives for 5 1/2 years." | 1.26 | Hepatocellular carcinoma in a young woman with prolonged exposure to oral contraceptives. ( Gattanell, PN; Holland, JF; Perloff, M, 1978) |
| "Although advanced gastrointestinal cancer is the most commonplace problem encountered by the medical oncologist, this group of diseases has proved exceedingly resistant to past chemotherapy efforts." | 1.25 | Clinical management of advanced gastrointestinal cancer. ( Moertel, CG, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (73.33) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, YL | 1 |
| Yu, SL | 1 |
| Su, KJ | 1 |
| Wei, CW | 1 |
| Jian, MH | 1 |
| Lin, PC | 1 |
| Tseng, IH | 1 |
| Lin, CC | 1 |
| Su, CC | 1 |
| Chan, DC | 1 |
| Lin, SZ | 1 |
| Harn, HJ | 1 |
| Chen, YL | 1 |
| Mann, BD | 1 |
| Kern, DH | 1 |
| Giuliano, AE | 1 |
| Burk, MW | 1 |
| Campbell, MA | 1 |
| Kaiser, LR | 1 |
| Morton, DL | 1 |
| Hanna, MG | 1 |
| Key, ME | 1 |
| Baril, BB | 1 |
| Baril, EF | 1 |
| Laszlo, J | 2 |
| Wheeler, GP | 1 |
| Moertel, CG | 2 |
| Bast, RC | 1 |
| Segerling, M | 1 |
| Ohanian, SH | 1 |
| Greene, SL | 1 |
| Zbar, B | 1 |
| Rapp, HJ | 1 |
| Borsos, T | 1 |
| Miyahara, M | 2 |
| Nakadate, M | 1 |
| Suzuki, I | 1 |
| Ishidate, M | 1 |
| Odashima, S | 1 |
| Gattanell, PN | 1 |
| Perloff, M | 1 |
| Holland, JF | 1 |
| Senzer, NN | 1 |
| Terrell, W | 1 |
| Pratt, CB | 1 |
| Chen, J | 1 |
| Zhang, Y | 1 |
| Sui, J | 1 |
| Chen, Y | 1 |
| Habraken, Y | 1 |
| Laval, F | 1 |
| Krakamp, B | 1 |
| Schmitz, R | 1 |
| Knöpfle, G | 1 |
| Leidig, P | 1 |
| Inaba, M | 1 |
| Sakurai, Y | 1 |
| Baril, E | 1 |
| Baril, B | 1 |
15 other studies available for carmustine and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Extended O6-methylguanine methyltransferase promoter hypermethylation following n-butylidenephthalide combined with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) on inhibition of human hepatocellular carcinoma cell growth.
Topics: Angelica sinensis; Antineoplastic Agents; Carcinoma, Hepatocellular; Carmustine; Cell Line, Tumor; C | 2010 |
Clinical correlations with drug sensitivities in the clonogenic assay: a retrospective study.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma; Carcinoma, Hepatocellular; Carmustine; Cell Division; D | 1982 |
Immunotherapy of metastases enhances subsequent chemotherapy.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; BCG Vaccine; Carcinoma, Hepatocellular; Carmusti | 1982 |
Inhibition of rat liver DNA polymerase by nitrosoureas and isocyanates.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carmustine; Cyanates; Cyclohexanes; Cyclo | 1975 |
Clinical management of advanced gastrointestinal cancer.
Topics: Adenoma, Islet Cell; Carcinoma, Hepatocellular; Carmustine; Colonic Neoplasms; Cytarabine; Drug Ther | 1975 |
Regression of established tumors and induction of tumor immunity by intratumor chemotherapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carmustine; Dacarbazine; Dactinomycin; Do | 1976 |
Walter Hubert lecture Chemotherapy of upper gastrointestinal carcinoma.
Topics: Adenoma, Islet Cell; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Hepatocellular; Carcinoma, S | 1976 |
Antitumor effect of 1,1'-polymethylene-bis (1-nitrosourea) and related compounds.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carmustine; Drug Evaluation, Preclinical; | 1977 |
Hepatocellular carcinoma in a young woman with prolonged exposure to oral contraceptives.
Topics: Adult; Carcinoma, Hepatocellular; Carmustine; Contraceptives, Oral; Contraceptives, Oral, Combined; | 1978 |
Evaluation of a chemotherapeutic regimen for primary liver cancer in children.
Topics: Adolescent; Antineoplastic Agents; Carcinoma, Hepatocellular; Carmustine; Child; Doxorubicin; Drug E | 1978 |
O6-methylguanine-DNA methyltransferase activity and sensitivity of human tumor cell lines to bis-chloroethylnitrosourea.
Topics: Carcinoma, Hepatocellular; Carmustine; Drug Resistance; Drug Synergism; Female; Humans; Liver Neopla | 1992 |
Enhancement of 1,3-bis(2-chloroethyl)-1-nitrosourea resistance by gamma-irradiation or drug pretreatment in rat hepatoma cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carmustine; Cisplatin; Combined Modality | 1991 |
[Primary and metastatic liver tumors--evaluation of tumor regression and response with regional cytostatic drug therapy by sonography and fine needle puncture histology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Hepatocellular; Carmustin | 1990 |
Combined effect of nitrogen mustard and DNA repair inhibitor on the resistant tumor.
Topics: Animals; Carcinoma, Hepatocellular; Carmustine; Cell Line; Cyanates; DNA Repair; Drug Resistance; Dr | 1974 |
DNA polymerases in normal and regenerating rat liver and hepatomas: targets for chemotherapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carmustine; Cell Fractionation; Cyanates; | 1974 |